Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy
Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy in Patients With Ragweed Pollinosis: a Phase III Randomized and Controlled Clinical Study
Sponsor: ALK-Abelló A/S
This PHASE3 trial investigates Pollen Allergy and is currently completed. ALK-Abelló A/S leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Sep 2017 [monthly]
Completed PHASE3
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ALK-Abelló A/S
- ASST Fatebenefratelli Sacco
For direct contact, visit the study record on ClinicalTrials.gov .